Page 2 - Every Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ortho Clinical Diagnostics Announces Launch of Initial Public Offering RARITAN, N.J., Jan. 19, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the launch of its initial public offering of its ordinary shares. Ortho is offering 70 million ordinary shares, with the initial public offering price expected to be between $20.00 and $23.00 per share. Ortho expects to grant the underwriters a 30-da...

Share this article Share this article - Ortho's VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). - With utility for mass-scale testing and same-day results for labs, Ortho's latest COVID-19 solution can run up to 130 tests per hour. - The test is run on Ortho's high-volume VITROS® Systems, which are installed in over 5,600 laboratories around the world with 1,500 installed in the U.S. RARITAN, N.J., Jan. 12, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vi...

Ortho's VITROS SARS-CoV-2 Antigen Test for Accurate, Mass-Scale COVID-19 Testing is the First High-Volume Test to Receive FDA Emergency Use Authorization i, clinically reliable results on Ortho's high-volume VITROS Systems, which are installed in over 5,600 laboratories around the world. More than 1,500 VITROS analyzers are operational across the U.S. - including more than 500 located in rural regions, where coronavirus testing needs are especially urgent. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run sa...